Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
How the Iran war may affect your money and bills- 'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Zendaya's 'Breaking Bad' era
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- When darkness shines: How dark stars could illuminate the early universe
- Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- 21 Things You Ought to Never Share with Your Childless Companion
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
